Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.
Haleon ups profit guidance as power brands deliver
Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of 4-6%.
Futura Medical: Haleon ready launch Eroxon in the US before the year-end
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction. In its results statement earlier Thursday, the consumer products giant said Eroxon would be available Stateside before the year-end.
Haleon sees high single-digit growth for annual organic operating profit
Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its oral care products and vitamins.
HLN vs. LMAT: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
Haleon to quieten 'noise' with latest update, broker suggests
Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility' this year, suggests broker Jefferies. From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
Haleon to sell nicotine replacement therapy business outside US for $633 mln
British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million).
